CNS manifestations of cytomegalovirus infections: diagnosis and treatment.

Abstract:

:Cytomegalovirus (CMV) infection of the CNS occurs most commonly in patients with severe immunosuppression such as those with advanced HIV infection (i.e. AIDS) or those who have undergone bone marrow or solid organ transplantation. Immunocompetent patients are affected very rarely. The infection of the CNS may affect the brain (diffuse encephalitis, ventriculoencephalitis, cerebral mass lesions) or the spinal cord (transverse myelitis, polyradiculomyelitis). Diagnosis is very difficult and should be based on clinical presentation, results of imaging and virological markers. The most specific diagnostic tool is the detection of CMV DNA by polymerase chain reaction in the CSF. Treatment should be initiated promptly if CMV infection is suspected. Antiviral therapy consists of intravenous ganciclovir, intravenous foscarnet or a combination of both. Cidofovir is the treatment of second choice. Patients who experience clinical improvement or stabilisation during induction therapy should be given maintenance therapy. After immune reconstitution (in HIV-positive patients) or discontinuation of immunosuppressive therapy (in transplant recipients), maintenance therapy may be stopped. Despite therapy, the prognosis for long-term survival is very poor, especially in patients with AIDS.

journal_name

CNS Drugs

journal_title

CNS drugs

authors

Maschke M,Kastrup O,Diener HC

doi

10.2165/00023210-200216050-00003

subject

Has Abstract

pub_date

2002-01-01 00:00:00

pages

303-15

issue

5

eissn

1172-7047

issn

1179-1934

pii

160503

journal_volume

16

pub_type

杂志文章,评审
  • Spotlight on oxcarbazepine in epilepsy.

    abstract::Oxcarbazepine (Trileptal, Timox) is structurally related to carbamazepine and has anticonvulsant activity. Studies suggest that the anticonvulsant activity of oxcarbazepine is mediated via the blocking of neuronal ion channels. In patients aged <18 years, the efficacy of oxcarbazepine monotherapy was similar to that o...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-200418010-00006

    authors: Bang LM,Goa KL

    更新日期:2004-01-01 00:00:00

  • Overview of Current Drug Delivery Methods Across the Blood-Brain Barrier for the Treatment of Primary Brain Tumors.

    abstract::Existing drug delivery methods have not led to a significant increase in survival for patients with malignant primary brain tumors. While the combination of conventional therapies consisting of surgery, radiotherapy, and chemotherapy has improved survival for some types of brain tumors (e.g., WNT medulloblastoma), oth...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00766-w

    authors: Haumann R,Videira JC,Kaspers GJL,van Vuurden DG,Hulleman E

    更新日期:2020-11-01 00:00:00

  • Potential of Glial Cell Modulators in the Management of Substance Use Disorders.

    abstract::The pervasive and devastating nature of substance use disorders underlies the need for the continued development of novel pharmacotherapies. We now know that glia play a much greater role in neuronal processes than once believed.  The various types of glial cells (e.g., astrocytes, microglial, oligodendrocytes) partic...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00721-9

    authors: Jones JD

    更新日期:2020-07-01 00:00:00

  • Pharmacokinetics and Clinical Utility of Valproic Acid Administered via Continuous Infusion.

    abstract:INTRODUCTION:Valproic acid is a versatile antiepileptic drug that is often used in the acute care setting. Intravenous valproic acid lends itself well to a continuous infusion as it exhibits a relatively short half-life. We evaluated the pharmacokinetics and clinical efficacy of continuous infusion valproic acid in hos...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-015-0304-5

    authors: Cook AM,Zafar MS,Mathias S,Stewart AM,Albuja AC,Bensalem-Owen M,Kapoor S,Baumann RJ

    更新日期:2016-01-01 00:00:00

  • Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

    abstract::Duloxetine (Cymbalta(R)) is a potent serotonin and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) in the CNS. It is indicated for the treatment of generalized anxiety disorder (GAD) as well as other indications. In patients with GAD of at least moderate severity, oral duloxetine 60-120 mg once daily was effe...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200923060-00006

    authors: Carter NJ,McCormack PL

    更新日期:2009-01-01 00:00:00

  • Female hypoactive sexual desire disorder: epidemiology, diagnosis and treatment.

    abstract::Female hypoactive sexual desire disorder (HSDD) may occur in up to one-third of adult women in the US. The essential feature of female HSDD is a deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. The evaluation of female HSDD generally requ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200216110-00003

    authors: Warnock JJ

    更新日期:2002-01-01 00:00:00

  • Lower IQ is associated with decreased clinical response to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.

    abstract:OBJECTIVES:Atomoxetine is commonly used to treat attention-deficit hyperactivity disorder (ADHD) in children with a broad range of cognitive abilities. We examined the association between level of cognitive functioning as determined by IQ and clinical response during treatment with atomoxetine. METHODS:The records of ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/11590450-000000000-00000

    authors: Mazzone L,Reale L,Mannino V,Cocuzza M,Vitiello B

    更新日期:2011-06-01 00:00:00

  • The glutamatergic system and Alzheimer's disease: therapeutic implications.

    abstract::Alzheimer's disease affects nearly 5 million Americans currently and, as a result of the baby boomer cohort, is predicted to affect 14 million Americans and 22 million persons totally worldwide in just a few decades. Alzheimer's disease is present in nearly half of individuals aged 85 years. The main symptom of Alzhei...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317090-00004

    authors: Butterfield DA,Pocernich CB

    更新日期:2003-01-01 00:00:00

  • Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action.

    abstract::The aim of this review is to provide clinicians with a picture of the mechanisms by which: histamine and histaminergic agonists act on the vestibular system both peripherally and centrally; and histaminergic agonists and antagonists interfere with the recovery process after peripheral vestibular lesion. We have focuse...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115110-00004

    authors: Lacour M,Sterkers O

    更新日期:2001-01-01 00:00:00

  • Aetiopathogenesis and pathophysiology of bulimia nervosa: biological bases and implications for treatment.

    abstract::Bulimia nervosa is an eating disorder characterised by recurrent episodes of binge eating and associated efforts to purge the ingested calories through self-induced vomiting, laxative or diuretic abuse, fasting or intensive exercise. The aetiopathogenesis and pathophysiology of the disorder are currently unclear. Biol...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115020-00004

    authors: Brambilla F

    更新日期:2001-01-01 00:00:00

  • Sodium Channel Blockers in the Treatment of Epilepsy.

    abstract::Sodium channel blockers have been the mainstay of the pharmacological management of focal and generalised tonic-clonic seizures for more than 70 years. The focus of this paper will be on phenytoin, carbamazepine, lamotrigine, oxcarbazepine, rufinamide, lacosamide and eslicarbazepine acetate. All these antiepileptic dr...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-017-0441-0

    authors: Brodie MJ

    更新日期:2017-07-01 00:00:00

  • Antipsychotic polypharmacy in schizophrenia: benefits and risks.

    abstract::Antipsychotic polypharmacy refers to the co-prescription of more than one antipsychotic drug for an individual patient. Surveys of prescribing in psychiatric services internationally have identified the relatively frequent and consistent use of combined antipsychotics, usually for people with established schizophrenia...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11587810-000000000-00000

    authors: Barnes TR,Paton C

    更新日期:2011-05-01 00:00:00

  • Evaluation of serum levels of chemokines during interferon-β treatment in multiple sclerosis patients: a 1-year, observational cohort study.

    abstract:BACKGROUND:The molecules that provide access to activated T cells in the CNS, including chemokines, have been considered to be a crucial step in the pathogenesis of multiple sclerosis (MS). AIMS:In this study, we investigated serial serum chemokine levels in patients with relapsing-remitting MS over 1 year and the ass...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/11595060-000000000-00000

    authors: Comini-Frota ER,Teixeira AL,Angelo JP,Andrade MV,Brum DG,Kaimen-Maciel DR,Foss NT,Donadi EA

    更新日期:2011-11-01 00:00:00

  • Pregabalin: as adjunctive treatment of partial seizures.

    abstract::Pregabalin, the pharmacologically active S-enantiomer of 3-aminomethyl-5-methylhexanoic acid, possesses anticonvulsant activity. Pregabalin binds with high affinity and specificity to voltage-gated calcium channel alpha(2)-delta proteins. The putative mechanism of action of the drug is reduced excitatory neurotransmit...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200519030-00007

    authors: Warner G,Figgitt DP

    更新日期:2005-01-01 00:00:00

  • Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database.

    abstract:BACKGROUND:Responses to atomoxetine vary for individual patients with attention-deficit/hyperactivity disorder (ADHD). However, we do not know whether any factors can be used to reliably predict how individuals with ADHD will respond to treatment. OBJECTIVE:Our objective was to evaluate background variables that facil...

    journal_title:CNS drugs

    pub_type: 临床试验,杂志文章

    doi:10.1007/s40263-016-0323-x

    authors: Bushe C,Sobanski E,Coghill D,Berggren L,De Bruyckere K,Leppämäki S

    更新日期:2016-04-01 00:00:00

  • Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders.

    abstract::Alcoholic patients suffer from harmful allostatic neuroplastic changes in the brain causing an acute withdrawal syndrome upon cessation of drinking followed by a protracted abstinence syndrome and an increased risk of relapse to heavy drinking. Benzodiazepines have long been the treatment of choice for detoxifying pat...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0240-4

    authors: Hammond CJ,Niciu MJ,Drew S,Arias AJ

    更新日期:2015-04-01 00:00:00

  • Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases.

    abstract:BACKGROUND:Thrombolytic therapy reduces stroke size and disability by reperfusion and salvage of ischaemic penumbra. Emerging evidence suggests that retrieved penumbra may be the site of ongoing inflammatory pathology that includes extensive microglial activation. Microglial activation may be associated with excessive ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/11588400-000000000-00000

    authors: Tobinick E

    更新日期:2011-02-01 00:00:00

  • Maternal Anti-Fetal Brain IgG Autoantibodies and Autism Spectrum Disorder: Current Knowledge and its Implications for Potential Therapeutics.

    abstract::Several studies have found a correlation between the presence of circulating maternal autoantibodies and neuronal dysfunction in the neonate. Specifically, maternal anti-brain autoantibodies, which may access the fetal compartment during gestation, have been identified as one risk factor for developing autism spectrum...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0279-2

    authors: Fox-Edmiston E,Van de Water J

    更新日期:2015-09-01 00:00:00

  • Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.

    abstract::Satisfactory management of Parkinson's disease is a challenge that requires a tailored approach for each individual. In the advanced phase of the disease, patients may experience motor complications despite optimized pharmacological therapy. Apomorphine, a short-acting D1- and D2-like receptor agonist, is the only dru...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-019-00661-z

    authors: Carbone F,Djamshidian A,Seppi K,Poewe W

    更新日期:2019-09-01 00:00:00

  • Therapeutic options for treatment-resistant depression.

    abstract::Treatment-resistant depression (TRD) presents major challenges for both patients and clinicians. There is no universally accepted definition of TRD, but results from the US National Institute of Mental Health's (NIMH) STAR*D (Sequenced Treatment Alternatives to Relieve Depression) programme indicate that after the fai...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11530280-000000000-00000

    authors: Shelton RC,Osuntokun O,Heinloth AN,Corya SA

    更新日期:2010-02-01 00:00:00

  • Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis.

    abstract:BACKGROUND:Cenobamate is a novel tetrazole-derived carbamate compound with a dual mechanism of action. This drug can enhance the inactivated state of voltage-gated sodium channels, preferentially inhibiting the persistent component of the sodium channel current, and acts as a positive allosteric modulator of GABAA rece...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00759-9

    authors: Lattanzi S,Trinka E,Zaccara G,Striano P,Del Giovane C,Silvestrini M,Brigo F

    更新日期:2020-11-01 00:00:00

  • Duloxetine: a review of its use in the treatment of major depressive disorder.

    abstract::Duloxetine (Cymbalta) is an orally administered, selective serotonin and noradrenaline reuptake inhibitor (SNRI) that has been approved for the treatment of major depressive disorder (MDD). Based on a considerable body of evidence, duloxetine at dosages ranging from 40 to 120 mg/day was effective in the short- and lon...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200721070-00004

    authors: Frampton JE,Plosker GL

    更新日期:2007-01-01 00:00:00

  • Ziprasidone.

    abstract::▴ Ziprasidone is a novel antipsychotic drug. It has high affinity for serotonin 5-HT(2) and dopamine D(2) receptors in vitro, with an 11-fold higher affinity for 5-HT(2) than for D(2) receptors, suggestive of a low potential for inducing motor disturbance [including extrapyramidal symptoms (EPS)].▴ The effects of zipr...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-199708020-00006

    authors: Davis R,Markham A

    更新日期:1997-08-01 00:00:00

  • Diclofenac potassium powder for oral solution: a review of its use in patients with acute migraine.

    abstract::Diclofenac potassium powder for oral solution (Voltfast(®), Catafast(®), Cambia(®); hereafter referred to as diclofenac potassium powder) is a non-steroidal anti-inflammatory drug (NSAID), and is indicated for the acute treatment of migraine. This article reviews the pharmacological properties of diclofenac potassium ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-014-0186-y

    authors: Garnock-Jones KP

    更新日期:2014-08-01 00:00:00

  • Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia.

    abstract:INTRODUCTION AND OBJECTIVE:Haemorrheological parameters and endothelial function are known to be altered in vascular diseases, including stroke. Treatment with HMG-CoA reductase inhibitors ('statins') improves cerebrovascular (and cardiovascular) morbidity and mortality in patients with atherosclerosis; the beneficial ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-200418030-00003

    authors: Szapary L,Horvath B,Marton Z,Alexy T,Kesmarky G,Habon T,Szots M,Koltai K,Juricskay I,Czopf J,Toth K

    更新日期:2004-01-01 00:00:00

  • Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia.

    abstract::Loxapine is a well-established, first-generation antipsychotic agent. Loxapine inhalation powder (Adasuve(®)) was recently approved in the USA and the EU for use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. Inhaled loxapine is delivered by a hand-held, single-dose, single-use...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0075-9

    authors: Keating GM

    更新日期:2013-06-01 00:00:00

  • The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review.

    abstract::The issue of antipsychotic treatment during pregnancy is subject to substantial uncertainty and some controversy among healthcare providers, specifically pertaining to second-generation antipsychotics (SGAs) that are subject to a large gap in safety data during pregnancy compared with antidepressants. The amount of sa...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0517-5

    authors: Damkier P,Videbech P

    更新日期:2018-04-01 00:00:00

  • Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety.

    abstract:BACKGROUND:Dravet syndrome (DS) is one of the most severe forms of drug-resistant epilepsy and available interventions fail to control seizures in most patients. Cannabidiol (CBD) is the first in a new class of antiepileptic drugs with a distinctive chemical structure and mechanism of action. OBJECTIVE:The aim of this...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00708-6

    authors: Lattanzi S,Brigo F,Trinka E,Zaccara G,Striano P,Del Giovane C,Silvestrini M

    更新日期:2020-03-01 00:00:00

  • Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs.

    abstract::Multiple sclerosis (MS) has a profound impact on health-related quality of life (HRQoL), a comprehensive subjective measure of the patient's health status. Assessment of HRQoL informs on the potential advantages and disadvantages of disease-modifying drugs (DMDs) beyond their effects on observer-based disability and m...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-017-0444-x

    authors: Jongen PJ

    更新日期:2017-07-01 00:00:00

  • Management of psychiatric comorbidity in anorexia nervosa and bulimia nervosa.

    abstract::The eating disorders anorexia nervosa and bulimia nervosa present with comorbidity in a number of important areas, including depression, bipolar disorder, anxiety disorders (obsessive-compulsive disorder, panic disorder, social anxiety disorder and other phobias, and post-traumatic stress disorder) and substance abuse...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620080-00004

    authors: Woodside BD,Staab R

    更新日期:2006-01-01 00:00:00